Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of Pemetrexed and folic acid as neoadjuvant treatment in resectable rectal cancer
2005-005929-62Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in rectal adenocarcinoma, sponsored by Eli Lilly and Company. Primary endpoint: Feasibility (planned total dose received). Started Mar 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2005-005929-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005929-62.